Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Journey Medical (DERM) GlobeNewswire News Room·2024-08-13 04:01
New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were 13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a co ...